Stability Enhancement of Drug Layered Pellets in a Fixed Dose Combination Tablet
Tóm tắt
Từ khóa
Tài liệu tham khảo
Deacon CF, Holst JJ. Review: dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol. 2006;38:831–44.
Von Gelderen TW, Trevillyan JM. “The Next Big Thing” in diabetes: clinical progress on DPP-IV inhibitors. Drug Dev Res. 2006;67:627–42.
Miller SA, St. Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006;40:1336–43.
Schlesselman LS. Vildagliptin: adipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Formulary. 2006;41:494–500.
Haffner CD, McDougald DL, Reister SM, Thompson BD, Conlee C, Fang J, Bass J, Lenhard JM, Croom D, Secosky-Chang MB, Tomaszek T, McConn D, Wells-Knecht K, Johnson PR. 2-Cyano-4-fluoro-1-thivalylpyrrolidine analogues as potent inhibitors of DPP-IV. Bioorg Med Chem Lett. 2005;15:5257–61.
Ahren B, Mills D, Gomis R, Schweizer A, Standl E. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874–80.
Vanderpoel D, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther. 2004;26:2066–75.
Turkoglu M, Varol H, Celikok M. Tableting and stability evaluation of enteric-coated omeprazole pellets. Eur J Pharm Biopharm. 2004;57:279–86.
Kuhl P, Mielck JB. Tabletting of pellet–matrix systems: ability of parameters from dynamic and kinetic models to elucidate the densification of matrix formers and of pellets. Int J Pharm. 2002;248:101–14.
Joshi B, Ramsey B, Johnson B, Patterson D, Powers J, Facchine K, Osterhout M, LeBlanc M, Bryant-Mills R, Copley R, Sides S. Elucidating the pathways of degradation of denagliptin. J Pharm Sci. 2010;99:3030–40.
Wang X, Cui F, Yonezawa Y, Sunada H. Preparation and evaluation of combination tablet containing incompatible active ingredients. Chem Pharm Bull. 2003;51:772–8.
Opadry II product information brochure (Pib_opadryII_v2_10.2009) 2009. http://www.colorcon.com/literature/marketing/fc/Opadry%20II/pib_opadryII.pdf . Accessed 06 Nov 2012.
Opadry AMB product information brochure (Pib_opadryam_v2_10.2009) 2009. http://www.colorcon.com/literature/marketing/fc/Opadry%20amb/pib_opadry_amb.pdf . Accessed 06 Nov 2012.
Okhamafe AO, Iwebor HU. Moisture permeability mechanisms of some aqueous-based tablet film coatings containing soluble additives. Die Pharm. 1987;42:611–3.
Budhlall BM, Landfester K, Sudol ED, Dimonie VL, Klein A, El-Aasser MS. Characterization of partially hydrolyzed poly(vinyl alcohol). Effect of poly(vinyl alcohol) molecular architecture on aqueous phase conformation. Macromolecules. 2003;36:9477–84.
Bajwa GS, Hoebler K, Sammon C, Timmins P, Melia CD. Microstructural imaging of early gel layer formation in HPMC matrices. J Pharm Sci. 2006;95:2145–57.